patients receiving metronidazole demonstrated a significant reduction in febrile morbidity ( from 48 to 8 % ) , infectious morbidity ( from 46 to 16 % ) , urinary tract infections ( from 30 to 10 % ) , and pelvic and/or abdominal wound infections ( from 18 to 2 % ) .
C0009450
infectious
C0042029
urinary tract infections